Biochips enable the accurate, rapid, and high-throughput detection of DNA, RNA, polypeptides, proteins, cells, tissues, and other biological components, with great advantages in disease screening and early diagnosis.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Early treatment ofautism spectrum disorder(ASD) can significantly improve the lives of affected children and their families, but diagnosing the disorder is often a challenge. A company in Syracuse, NY hasdeveloped an epigenetic test that cou

Researchers from Aromyx Corp. announced this month that the companys flagship technology, the EssenceChip, will be made available to select partners by the end of this year. The new biosensor technology was designed to work with a digital pl

doesnt shy away from speaking about biocompatibility topics related to medical devices. Turley serves as a senior biocompatibility expert for Nelson Labs. The Salt Lake City, UT-based lab serves as an independent consultant that can help nav

An Epic Approach Toward Liquid Biopsy 液体活检 史诗般的方法 The liquid biopsy space continues to attract investors and bring in financings that are typically above the average amount medtech firms are able to raise. Epic Sciences

Medical device designers have a new research tool in their arsenal that facilitates faster immersion for the development team and provides a communication platform to bring patients and healthcare professionals into the development process.

Biodesix Makes the Case for VeriStrat Through New Study Biodesix通过新的研究证明了VeriStrat的可行性 The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncol

Ortho Clinical Diagnostics, a global leader in diagnostic platforms and technologies, recently announced that its new digital chemistry system known as the VITROS XT 7600 has received the CE mark ahead of its launch overseas. The new technol

Bacterial or viral infection, that is the question. Haifa-Israel based MeMed Diagnostics is developing a point-of-care platform and immune-based test that will one day be able to provide answers. Such a test could help with the overuse and u

Nebula Genomics has raised $4.3 million in seed financing from venture capital firms and has also partnered with Veritas Genetics, the company said recently. Nebula, which was founded last year by Harvard University researchers including Ge

Nebula Genomics has raised $4.3 million in seed financing from venture capital firms and has also partnered with Veritas Genetics, the company said recently. Nebula, which was founded last year by Harvard University researchers including Ge